Uveitis News and Research

RSS

Uveitis is an inflammation of the uvea. The uvea is the front part of the eye. It includes the iris, which is the colored part of the eye, and the parts right next to and behind the iris. Uveitis may hurt a lot of parts of the eye. It may last as long as six weeks, or it may last a shorter time.

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

1 Oct 2013

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.

1 Oct 2013

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Excellence issued draft guidance recommending ILUVIEN for the treatment of pseudophakic patients (those who have undergone prior cataract surgery) with chronic diabetic macular edema considered insufficiently responsive to available therapies.

15 Jun 2013

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

Ocular tuberculosis presents a diagnostic challenge

Mycobacterial ocular inflammation typically arises without concomitant systemic or pulmonary disease and should be suspected in patients who do not respond to anti-inflammatory therapy.

29 Apr 2013

pSivida announces resubmission of ILUVIEN NDA to FDA for chronic diabetic macular edema

pSivida Corp., a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc. reported the submission of its response to the second Complete Response Letter from the U.S. Food and Drug Administration with respect to ILUVIEN for chronic diabetic macular edema.

2 Apr 2013

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Sucampo Pharmaceuticals, Inc. today announced that RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% is now available by prescription across the United States. The U.S. Food and Drug Administration (FDA) approved a sNDA for RESCULA for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension on December 7, 2012.

19 Feb 2013

Spain approves pSivida’s ILUVIEN to treat chronic diabetic macular edema

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the Spanish Agency of Drugs and Medical Devices (Agencia Espanola de Medicamentos y Productos Sanitarios) granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

18 Jan 2013

Apitope announces completion of recruitment in ATX-MS-1467 Phase I trial for MS

Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS).

26 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

pSivida reports revenues of $699,000 for fourth quarter 2012

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012.

25 Sep 2012

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease.

11 Sep 2012

New compound effective at blocking damage to the retina in diabetic retinopathy

Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because it could lead to a novel therapy that targets two mechanisms at the root of the disease: inflammation and the weakening of the blood barrier that protects the retina.

30 Jul 2012

FDA clears pSivida's IND for injectable sustained-release micro-insert to treat posterior uveitis

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to treat posterior uveitis with pSivida's injectable sustained-release micro-insert.

20 Jul 2012

Enrollment complete in Lux Biosciences Luveniq Phase 3 study for non-infectious uveitis

Lux Biosciences, Inc. today announced the completion of patient enrollment in its Phase 3 clinical study of Luveniq (oral voclosporin) for the treatment of non-infectious uveitis. Lux Biosciences anticipates that data from the Phase 3 study will be available early in the first quarter of 2013.

9 Jul 2012

Metformin blocks uveitis in laboratory rats

University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.

8 May 2012

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

OphthaliX announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis

10 Apr 2012

XMetA can control blood glucose levels in patients with diabetes

XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.

8 Mar 2012

Can-Fite receives FDA Orphan Drug Status for CF102 to treat hepatocellular carcinoma

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate, CF102, for the treatment of hepatocellular carcinoma.

23 Feb 2012

FDA approves preservative-free drug for glaucoma

The U.S. Food and Drugs Administration (FDA) has approved tafluprost ophthalmic solution (Zioptan, Merck) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution for glaucoma.

15 Feb 2012